Montana
The path to a better tuberculosis vaccine runs through Montana
A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.
The BCG (Bacille Calmette-Guérin) vaccine, created in 1921, remains the sole TB vaccine. While it is 40% to 80% effective in young children, its efficacy is very low in adolescents and adults, leading to a worldwide push to create a more powerful vaccine.
One effort is underway at the University of Montana Center for Translational Medicine. The center specializes in improving and creating vaccines by adding what are called novel adjuvants. An adjuvant is a substance included in the vaccine, such as fat molecules or aluminum salts, that enhances the immune response, and novel adjuvants are those that have not yet been used in humans. Scientists are finding that adjuvants make for stronger, more precise, and more durable immunity than antigens, which create antibodies, would alone.
Eliciting specific responses from the immune system and deepening and broadening the response with adjuvants is known as precision vaccination. “It’s not one-size-fits-all,” said Ofer Levy, a professor of pediatrics at Harvard University and the head of the Precision Vaccines Program at Boston Children’s Hospital. “A vaccine might work differently in a newborn versus an older adult and a middle-aged person.”
The ultimate precision vaccine, said Levy, would be lifelong protection from a disease with one jab. “A single-shot protection against influenza or a single-shot protection against COVID, that would be the holy grail,” Levy said.
Jay Evans, the director of the University of Montana center and the chief scientific and strategy officer and a co-founder of Inimmune, a privately held biotechnology company in Missoula, said his team has been working on a TB vaccine for 15 years. The private-public partnership is developing vaccines and trying to improve existing vaccines, and he said it’s still five years off before the TB vaccine might be distributed widely.
It has not gone unnoticed at the center that this state-of-the-art vaccine research and production is located in a state that passed one of the nation’s most extreme anti-vaccination laws during the pandemic in 2021. The law prohibits businesses and governments from discriminating against people who aren’t vaccinated against COVID-19 or other diseases, effectively banning both public and private employers from requiring workers to get vaccinated against COVID or any other disease. A federal judge later ruled that the law cannot be enforced in health care settings, such as hospitals and doctors’ offices.
In mid-March, the Bill & Melinda Gates Medical Research Institute announced it had begun the third and final phase of clinical trials for the new vaccine in seven countries. The trials should take about five years to complete. Research and production are being done in several places, including at a manufacturing facility in Hamilton owned by GSK..
Known as the forgotten pandemic, TB kills up to 1.6 million people a year, mostly in impoverished areas in Asia and Africa, despite its being both preventable and treatable. The U.S. has seen an increase in tuberculosis over the past decade, especially with the influx of migrants, and the number of cases rose by 16% from 2022 to 2023. Tuberculosis is the leading cause of death among people living with HIV, whose risk of contracting a TB infection is 20 times as great as people without HIV.
“TB is a complex pathogen that has been with human beings for ages,” said Alemnew Dagnew, who heads the program for the new vaccine for the Gates Medical Research Institute. “Because it has been with human beings for many years, it has evolved and has a mechanism to escape the immune system. And the immunology of TB is not fully understood.”
The University of Montana Center for Translational Medicine and Inimmune together have 80 employees who specialize in researching a range of adjuvants to understand the specifics of immune responses to different substances. “You have to tailor it like tools in a toolbox towards the pathogen you are vaccinating against,” Evans said. “We have a whole library of adjuvant molecules and formulations.”
Vaccines are made more precise largely by using adjuvants. There are three basic types of natural adjuvants: aluminum salts; squalene, which is made from shark liver; and some kinds of saponins, which are fat molecules. It’s not fully understood how they stimulate the immune system. The center in Missoula has also created and patented a synthetic adjuvant, UM-1098, that drives a specific type of immune response and will be added to new vaccines.
One of the most promising molecules being used to juice up the immune system response to vaccines is a saponin molecule from the bark of the quillay tree, gathered in Chile from trees at least 10 years old. Such molecules were used by Novavax in its COVID vaccine and by GSK in its widely used shingles vaccine, Shingrix. These molecules are also a key component in the new tuberculosis vaccine, known as the M72 vaccine.
But there is room for improvement.
“The vaccine shows 50% efficacy, which doesn’t sound like much, but basically there is no effective vaccine currently, so 50% is better than what’s out there,” Evans said. “We’re looking to take what we learned from that vaccine development with additional adjuvants to try and make it even better and move 50% to 80% or more.”
By contrast, measles vaccines are 95% effective.
According to Medscape, around 15 vaccine candidates are being developed to replace the BCG vaccine, and three of them are in Phase III clinical trials.
One approach Evans’ center is researching to improve the new vaccine’s efficacy is taking a piece of the bacterium that causes TB, synthesizing it, and combining it with the adjuvant QS-21, made from the quillay tree. “It stimulates the immune system in a way that is specific to TB and it drives an immune response that is even closer to what we get from natural infections,” Evans said.
The University of Montana center is researching the treatment of several problems not commonly thought of as treatable with vaccines. They are entering the first phase of clinical trials for a vaccine for allergies, for instance, and first-phase trials for a cancer vaccine. And later this year, clinical trials will begin for vaccines to block the effects of opioids like heroin and fentanyl.
The University of Montana received the largest grant in its history for anti-opioid vaccine research. It works by creating an antibody that binds with the drug in the bloodstream, which keeps it from entering the brain and creating the high.
For now, though, the eyes of health care experts around the world are on the trials for the new TB vaccines, which, if they are successful, could help save countless lives in the world’s poorest places.
2024 KFF Health News. Distributed by Tribune Content Agency, LLC.
Citation:
The path to a better tuberculosis vaccine runs through Montana (2024, April 29)
retrieved 29 April 2024
from https://medicalxpress.com/news/2024-04-path-tuberculosis-vaccine-montana.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
WASHINGTON — Montana voters will select nominees in Tuesday’s state primary to replace departing Republican incumbents in the U.S. Senate and House, but one major contender won’t be on the ballot. Meanwhile, several state legislative primaries will highlight divisions within Montana’s dominant Republican Party.
Republicans hold slim majorities in both chambers of Congress. Montana has not been at the top of the list of seats Democrats hope to flip to regain control of either body, but the retirements do creak open the door for a candidate to possibly take advantage of the state’s independent streak.
Republican U.S. Sen. Steve Daines is not seeking a third term. He has endorsed former U.S. Attorney Kurt Alme to replace him. Daines’ late withdrawal from the race in March and the launch of Alme’s candidacy, both timed to occur just before the filing deadline, appeared to be carefully choreographed. President Donald Trump seemed to confirm as much in his endorsement of Alme.
“In fact, if Kurt didn’t have the highest level of aptitude and talent, Steve would have remained exactly where he is….” Trump said in a social media post.
Alme also has endorsements from the state’s other top Republicans, U.S. Sen. Tim Sheehy and Gov. Greg Gianforte. He faces Republicans Lee Calhoun and Charles Walking Child for the nomination.
The Democratic field includes former state Rep. Reilly Neill, whose fundraising is five times the combined haul of her four primary rivals.
The winners of both primaries will face former University of Montana president Seth Bodnar, who is running as an independent. As of mid-May, Bodnar had outraised the entire field of candidates, regardless of party. Bodnar is one of a handful of independent candidates who have opted to bypass the party primary process and could complicate the general election for some Republican incumbents.
In the 1st Congressional District, Republican U.S. Rep. Ryan Zinke is not seeking a fourth full term, citing health concerns. He, Trump, Sheehy and Gianforte have endorsed talk radio host and former Zinke congressional staffer Aaron Flint over Montana Secretary of State Christi Jacobsen, former state Sen. Al Olszewski and former high school government teacher Ray Curtis. The Democratic field includes former gubernatorial candidate Ryan Busse and union organizer Sam Forstag.
In the state Legislature, several primaries expose an ongoing rift within the ranks of Montana Republicans.
At the start of the 2025 legislative session, nine Republican state senators bucked the party on a variety of key floor measures, essentially handing control of the chamber to Democrats.
State Sen. Shelley Vance of District 34 is the only one of the maverick lawmakers, dubbed the “Nasty Nine” by the Montana GOP, up for reelection in 2026. Two others, state Sens. Jason Ellsworth and Bruce Gillespie, opted instead to run for the state House in Districts 34 and 18, respectively. The other six are either term-limited, retiring or not up this cycle.
In response to the revolt within the Republican caucus, the Montana Republican Party released a list of state legislative candidates it supports, including some who are challenging Republican incumbents in the state House. But some of the state party’s picks put the committee at odds with Gianforte, who has released a series of social media videos appearing with four state House incumbents targeted by the party.
The governor offered words of support for state House Speaker Brandon Ler and state Reps. Valerie Moore and Ken Walsh, who are all running for reelection, and for state Rep. Eric Albus, who is running in state Senate District 14. Gianforte does not explicitly endorse the lawmakers in the videos, but he called one a “great partner” and said he was “proud of the work” he’d done with another.
Half of the state’s 50 state Senate seats and all 100 state House seats are up for election in 2026.
Here are some of the key facts about the election and data points the AP Decision Team will monitor as the votes are tallied:
When do polls close?
Polls close at 8 p.m. MT, which is 10 p.m. ET.
What’s on the ballot?
The AP will provide vote results and declare winners in contested primaries for U.S. Senate, U.S. House, Public Service Commission, state Senate and state House.
Who gets to vote?
Any eligible voter may participate in any party’s primary.
How many voters are there?
As of May 25, there were about 791,000 registered voters in Montana. Voters do not register by party.
How many people actually vote?
About 190,000 Republican primary votes and about 108,000 Democratic primary votes were cast in the 2024 U.S. Senate primaries.
How much of the vote is cast early or by absentee ballot?
About 68% of the 2024 primary vote was cast before primary day.
As of Friday, about 166,000 ballots had already been cast in Tuesday’s election.
When are early and absentee votes released?
Counties vary in how they release votes. In previous elections, results from absentee voting mostly were released along with in-person Election Day voting throughout the night. About two-thirds of Montana’s 56 counties tend to release all or almost all of their mail and in-person early voting results in the first vote update of the night, often along with results from in-person Election Day voting. About half the counties tend to release all or almost all their in-person Election Day results in the first vote report.
How long does vote-counting usually take?
In the 2024 U.S. Senate primary, the AP first reported results at 10:26 p.m. ET, or 26 minutes after polls closed. The last vote update of the night was at 4:06 a.m. ET with about 84% of total votes counted.
When will the AP declare a winner?
The Associated Press does not make projections and will declare a winner only when it’s determined there is no scenario that would allow a trailing candidate to close the gap. If a race has not been called, the AP will continue to cover any newsworthy developments, such as candidate concessions or declarations of victory. In doing so, the AP will make clear that it has not yet declared a winner and explain why.
How do recounts work?
Montana requires an automatic recount only in the event of a tie vote. A candidate may request a recount if the margin is less than 0.5% of the total vote, but the state will only pay for it if the margin is 0.25% or less. The AP may declare a winner in a race that is subject to a recount if it can determine the lead is too large for a recount or legal challenge to change the outcome.
Are we there yet?
As of Tuesday, there will be 154 days until the 2026 midterm elections.
The Montana Lottery offers multiple draw games for those aiming to win big.
Here’s a look at May 31, 2026, results for each game:
Winning Big Sky Bonus numbers from May 31 drawing
06-19-26-31, Bonus: 03
Check Big Sky Bonus payouts and previous drawings here.
Winning Millionaire for Life numbers from May 31 drawing
03-11-26-45-56, Bonus: 05
Check Millionaire for Life payouts and previous drawings here.
Feeling lucky? Explore the latest lottery news & results
When are the Montana Lottery drawings held?
- Powerball: 8:59 p.m. MT on Monday, Wednesday, and Saturday.
- Mega Millions: 9 p.m. MT on Tuesday and Friday.
- Lucky For Life: 8:38 p.m. MT daily.
- Lotto America: 9 p.m. MT on Monday, Wednesday and Saturday.
- Big Sky Bonus: 7:30 p.m. MT daily.
- Powerball Double Play: 8:59 p.m. MT on Monday, Wednesday, and Saturday.
- Montana Cash: 8 p.m. MT on Wednesday and Saturday.
- Millionaire for Life: 9:15 p.m. MT daily.
Missed a draw? Peek at the past week’s winning numbers.
This results page was generated automatically using information from TinBu and a template written and reviewed by a Great Falls Tribune editor. You can send feedback using this form.
-
Politics4 minutes agoTrump admin backs off controversial $2B fund, clearing path for stalled GOP immigration bill
-
Health7 minutes agoEveryday task may help detect early dementia signs before diagnosis, study finds
-
Sports12 minutes agoFormer IndyCar driver Rick Treadway dies in motorcycle crash at 56
-
Technology19 minutes agoAI helped researchers bypass Apple M5 defenses
-
Business22 minutes agoAI company Anthropic files to list shares, heating up race with OpenAI
-
Entertainment27 minutes agoRonald LaPread, Commodores’ co-founder and bassist, dies at 75
-
Lifestyle34 minutes agoHoover Dam, challenged by drought, now wears a U.S. flag the size of a football field
-
Politics37 minutes ago’60 Minutes’ veteran Scott Pelley rips CBS News bosses, saying they are ‘murdering’ the program
